You are here

  • Home
  • Archive
  • Volume 72, Issue 10
  • A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

Citation Tools

Article menu
Clinical and epidemiological research
Extended report
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Park W, Hrycaj P, Jeka S, et al
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
Annals of the Rheumatic Diseases 2013;72:1605-1612.